Beiley Biofund Inc. (TPEX:7882)

Market Cap	5.05B
Revenue (ttm)	905.49M +330.1%
Net Income	793.94M +458.5%
EPS	3.73 +459.7%
Shares Out	212.47M
PE Ratio	6.37
Forward PE	n/a
Dividend	1.35 (5.70%)
Ex-Dividend Date	Sep 3, 2026

Volume	246,543
Open	23.70
Previous Close	24.30
Day's Range	22.80 - 23.95
52-Week Range	17.01 - 32.42
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Beiley Biofund

Beiley Biofund Inc. is a venture capital firm specializing in early-stage and late-stage investments. The firm seeks to invest in unmet medical needs, including chronic diseases associated with aging and cancer. It invests in biotechnology trends driven by precision medicine, artificial intelligence, and emerging platform technologies. The firm seeks to invest in novel drugs, medical devices, healthcare services, and veterinary medicine. Beiley Biofund Inc. was founded in 2013 and is based in Taipei, Taiwan.

• Industry: Management Investment Offices, Open-End
• Founded: 2013
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7882

Financial Performance

In 2025, Beiley Biofund's revenue was 1.23 billion, an increase of 773.27% compared to the previous year's 140.54 million. Earnings were 1.13 billion, an increase of 1066.28%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Nov 7, 2026

Data Sources Report a data error